Transgene Biotek Ltd Approves Q1 Results, Appoints New Internal Auditors
Transgene Biotek Ltd announced that its Board of Directors reviewed and approved the Unaudited Financial Results (Standalone and Consolidated) and the Limited Review Report for the quarter ended June 30, 2026. The board meeting also addressed strategic matters including extending the deadline for the Annual General Meeting and appointing a new Internal Auditor.The company’s Board of Directors held a meeting on August 7, 2026, during which several key decisions were made. These included approving the Unaudited Financial Results (both Standalone and Consolidated) for the quarter ending June 30, 2026, along with the corresponding Limited Review Report. Furthermore, the Board approved the extension of the Annual General Meeting (AGM) date for the financial year 2025-26 and sanctioned the appointment of M/s. Manisha Dubey & Associates as Internal Auditors for the financial year 2026-27.
Financial Performance Snapshot (Unaudited, Q1 FY2026)
The company reported its Unaudited Standalone and Consolidated Financial Results in Lakhs. Key figures reflecting the performance for the quarter ending June 30, 2026, are presented below:| Particulars | Q Ended 30-06-2026 (Unaudited) | Year to Date (Q1 FY2026) |
|---|---|---|
| Revenue from operations | 6.00 | 6.00 |
| Total income | 6.00 | 6.00 |
| Total expenses | 44.90 | 44.90 |
| Profit before tax | -38.90 | -38.90 |
| Profit for the year (Total comprehensive income) | -38.90 | -38.90 |
| Earnings per equity share (Basic/Diluted) | 757.70 / (0.05) | 757.70 / (0.05) |
The detailed unaudited standalone financial results for the quarter ended June 30, 2026, are as follows:
| Sr. No. | Particulars | Q Ended 30-06-2026 (Unaudited) | Year to Date (Q1 FY2026) |
|---|---|---|---|
| 1 | Revenue from operations | 6.00 | 6.00 |
| 3 | Total income | 6.00 | 6.00 |
| 5 | Profit before tax | -38.90 | -38.90 |
| 9 | Profit for the year (Total comprehensive income) | -38.90 | -38.90 |
| 12 | Earnings per equity share | 757.70 / (0.05) | 757.70 / (0.05) |
Independent Audit and Review Status
The company's unaudited consolidated financial results were subject to a review conducted by M/S Vasavi & Co, Chartered Accountants. The independent auditor noted that the Statement was prepared in accordance with Indian Accounting Standard 34 'Interim Financial Reporting.' Based on their procedures, the auditors stated that nothing came to their attention that suggests the accompanying Statement has not disclosed the required information or contains any material misstatement.The appointment of M/s Manisha Dubey & Associates as Internal Auditors for the financial year 2026-27 was approved by the Board. The firm is led by Ms. Manisha Dubey, who possesses over 24 years of experience in internal audit and Internal Financial Controls reviews.
Details regarding the newly appointed internal auditors are provided below:
| Particulars | Details |
|---|---|
| Name of Auditors | M/s. Manisha Dubey & Associates, Chartered Accountants |
| Reason for appointment | Appointment of a Peer Reviewed Firm of Chartered Accountant in Practice |
| Date and Term of Appointment | Approved by the Board on August 07, 2026, for the financial year 2026-27 |
| Profile Summary | Ms. Manisha Dubey is the Sole Proprietor, with over 24 years' experience in internal audit and Internal Financial Controls reviews. |
Stock Price Movement
Transgene Biotek Ltd. is ticking up 2.75% as of 11:43, trading at ₹2.99. The shares have moved tightly within their intraday range, with a low of ₹2.98 and the current price sitting just shy of its high.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.